Frost & Sullivan to Host Quarterly Analyst Briefing on Cancer Market Growth on
Thursday, September 1, 2005
PALO ALTO, Calif., Aug. 29 /PRNewswire/ -- The Healthcare Group at Frost &
Sullivan is pleased to announce its Exclusive Healthcare 2005 Quarterly
Analyst Briefing Presentation on cancer market growth to be held on Thursday,
September 1, 2005 at 12:00pm CDT / 1:00pm EDT.
The cancer therapy market is undergoing a shift in the revenue generation.
The older chemotherapeutic drugs are no longer the sole source of revenue
generation and the future of this market is dependent upon the success of
targeted therapies. These therapies, such as Rituxan/MabThera and Glivec are
already dominating their markets in terms of revenues and this trend of
targeted therapies is now moving into the larger cancers that have tremendous
patient population. The question is, can targeted therapies be as successful
as they need to be to drive revenue and at the same time provide substantial
benefit to patients?
The briefing will analyze targeted therapy markets, including analysis of
the top targeted therapies currently on the market and the significant
targeted therapies expected to enter the market in the next five years. The
strategies of development will be assessed along with market potential. The
emerging trend of targeted therapies competing against each other will also be
addressed.
"The targeted therapy segment in the global cancer market is expected to
drive revenue growth through 2011. Targeted therapies are used in conjunction
with chemotherapy and therefore provide market expansion instead of
competition with existing agents," says Frost & Sullivan's Research Analyst
for the Pharmaceuticals group, Jason McKinnie. "Pharmaceutical and
biotechnology companies are focusing more attention on specific cancer targets
and are embracing targeted therapy as the future of cancer treatment."
Frost & Sullivan will hold this conference call at 12:00 pm (CDT) /
1:00 pm (EDT) on Thursday, September 1, 2005, which will provide industry
participants an outlook of the cancer market growth. To participate, please
email Melina Gonzalez at melina.gonzalez@frost.com with the following
information: your full name, company name, title, telephone number, e-mail
address, city, state, and country. Upon receipt of the above information, a
registration link will be emailed to you.
Frost & Sullivan, a global growth consulting company, has been partnering
with clients to support the development of innovative strategies for more than
40 years. The company's industry expertise integrates growth consulting,
growth partnership services, and corporate management training to identify and
develop opportunities. Frost & Sullivan serves an extensive clientele that
includes Global 1000 companies, emerging companies, and the investment
community by providing comprehensive industry coverage that reflects a unique
global perspective and combines ongoing analysis of markets, technologies,
econometrics, and demographics. For more information, visit
http://www.frost.com .
Contact:
Melina Gonzalez
North America Corporate Communications, Healthcare
P: 210.247.2403
F: 210.348.1003
E: melina.gonzalez@frost.com
http://www.frost.com
SOURCE Frost & Sullivan
 back to top
Related links:
http://www.frost.com
CONTACT:
Melina Gonzalez, North America Corporate
Communications, Healthcare of Frost & Sullivan, +1-210-247-2403,
or fax, +1-210-348-1003, or melina.gonzalez@frost.com
|
